See how your answers relate to your colleagues'.


The HypoDE randomized control trial demonstrated that:
a. Usage of RT-CGM reduced the number of hypoglycemic events in individuals with type 2 diabetes treated by MDI and with impaired hypoglycemia awareness or severe hypoglycemia
b. Usage of RT-CGM reduced the number of hypoglycemic events in individuals with type 1 diabetes treated by MDI and with impaired hypoglycemia awareness or severe hypoglycemia
c. The mean number of hypoglycemic events per 28 days among participants in the RT-CGM group was reduced from 10.8 to 2.2
d. Usage of RT-CGM is not predictable in 28 days and longer studies are recommended

Submit
cgmEDUCATION.net is supported by independent educational grants from Insulet Corporation, Madrigal Pharmaceuticals, MannKind Corporation, Medtronic, Stanford University, and Tandem Diabetes Care, Inc.
©2024 CogniMed Inc. All rights reserved.